item management s discussion and analysis of financial condition and results of operations this annual report may contain predictions  estimates and other forward looking statements that involve a number of risks and uncertainties  including those discussed earlier at risks and uncertainties 
while this outlook represents our current judgment on the future direction of our business  such risks and uncertainties could cause actual results to differ materially from any future performance suggested below 
we undertake no obligation to release publicly the results of any revisions to these forward looking statements to reflect events or circumstances arising after the date of this annual report 
the following discussion should be read in conjunction with our consolidated financial statements and the notes thereto 
overview of our business we develop  manufacture and market products that provide information to doctors performing minimally invasive  general surgical  cardiac surgical and other selected microsurgical procedures 
we have not yet generated substantial revenues from the sales of these products since our formation in july we expect to continue to incur substantial losses for at least the next months 
as of december   our accumulated deficit was approximately  we are not certain that our development efforts will result in commercially available products  that we will be successful in introducing new products under development  or that required regulatory approval of products will continue to be obtained in a timely manner  if at all 
at december   and  we had  and employees  respectively 
the number of our employees decreased in as a result of an internal restructuring whereby we closed part of our westborough operations and consequently reduced staffing 
we expect staffing to continue to increase modestly in the near term to approximately employees and stabilize at or near that level for the balance of our fiscal year our expectation is based on the fact that significant development work on our core platform technology is now complete and on strategic decisions to partner rather than develop an independent distribution capability 
our results of operations year ended december  compared with year ended december  sales we had revenues from product sales of  and  for the years ended december  and respectively 
the increase in revenues during was primarily due to revenues generated from our laparoscopic bariatric surgery program  which became an area of focus in sales to individual customers exceeding or more of revenues in the years ended december  were as follows during three customers accounted for  and of revenues  respectively  during  three customers accounted for  and of revenues  respectively  and during  two customers accounted for and of revenues respectively 
costs and expenses cost of sales 
our cost of sales were  and  for the years ended december  and  respectively 
the decrease in cost of sales during was primarily due to a reduction in manufacturing overhead expenses during compared to research and development expenses 
our research and development expenses were  and  for the years ended december  and  respectively 
the decrease in research and development expenses during was primarily attributable to decreases in staffing and related supply and occupancy costs and a decrease in contract services related to development efforts 
sales and marketing expenses 
our sales and marketing expenses were  and  for the years ended december  and  respectively 
the decrease in sales and marketing expenses during reflects a reduction in staffing and related expenses as a result of an internal restructuring and a one time  sales expense reversal in connection with the termination of our distribution agreement with medtronic 
general and administrative expenses 
our general and administrative expenses were  and  for the years ended december  and  respectively 
the decrease during was primarily due to a reduction in staffing and related expenses and a reduction in deferred compensation expense 
restructuring expenses 
we recorded credits for restructuring charges of  and charges of  for the years ended december  and  respectively 
restructuring credits during are primarily attributable to us subleasing the second floor space of our facility in westborough  massachusetts 
the expenses in relate to our decision to close part of our facilities in westborough  after a significant reduction in our workforce during the third quarter of and represented the value of continuing lease obligations  prior to arranging subleases 
other income and losses interest income 
our net interest income was  and  for the years ended december  and  respectively 
the decrease in was due primarily to decreasing average cash balances 
other gains and losses 
we had no other gains or losses for the year ended december  and other gains of  for the year ended december  the gains during relate to proceeds obtained from a sale of securities in connection with an earlier license agreement signed in with imagyn medical technologies  inc formerly urohealth systems  inc taxes at december   we had federal and state tax loss carryforwards of approximately  and  respectively 
the federal tax loss carryforwards will expire in approximately  of the state tax loss carryforwards expired in and will continue to expire in unless previously utilized 
at december   we also had federal and state research tax credit carryforwards of approximately  and  respectively  which will begin to expire in unless previously utilized 
we have provided a full valuation allowance on the deferred tax assets as realization of such assets is uncertain 
year ended december  compared with year ended december  sales we had revenues from product sales of  and  for the years ended december  and  respectively 
the decrease in revenues from to was due to a reduction in sales of stereosite systems  which we no longer sell  and associated distribution fees paid by sofamor danek  one of our former distributors  as well as a reduction in sales of our series advanced visualization and information system for minimally invasive cardiac surgery during these reductions were partially offset by higher sales of original equipment manufacturer products  including deliveries to a second customer in  by product deliveries to a second distributor for the head  neck and spine market during and by product sales to oec medical subsequently acquired by general electric for the medical imaging market during the period 
costs and expenses cost of sales 
our cost of sales were  and  for the years ended december  and  respectively 
the increase in cost of sales during was primarily due to significant inventory reserve charges we took in compared to  partially offset by lower product sales levels during and a reduction in manufacturing overhead expenses during compared to research and development expenses 
our research and development expenses were  and  for the years ended december  and  respectively 
the decrease in research and development expenses was primarily attributable to decreases in staffing and related supply and occupancy costs and a decrease in contract services related to development efforts 
sales and marketing expenses 
our sales and marketing expenses were  and  for the years ended december  and  respectively 
the decrease in sales and marketing expenses reflects the transition of all sales  marketing and distribution efforts associated with our series for minimally invasive cardiac surgery in the united states to a distributor at the end of june and a reduction in staffing and related expenses as a result of a restructuring completed during the third quarter of general and administrative expenses 
our general and administrative expenses were  and  for the years ended december  and  respectively 
the decrease was primarily due to a reduction in staffing and related expenses following a second quarter restructuring in  a reduction in deferred compensation expense and lower professional  legal and consulting service fees 
restructuring expenses 
we recorded restructuring charges of  and  during the years ended december  and  respectively 
the restructuring expenses during relate to a decision to close part of our facilities in westborough  massachusetts after a significant reduction in our workforce during the third quarter of and represents the value of continuing lease obligations 
the restructuring charges in related primarily to termination and severance payments to employees in connection with transfer of sales and marketing responsibility in the united states for our series system for minimally invasive cardiac surgery to a third party distributor  termination and severance payments to employees in connection with a general restructuring and work force reduction  and write down of assets related to a strategic decision to discontinue distribution of a line of cardiac instruments and sutures earlier than previously planned 
other income and losses interest income 
our net interest income was  and  for the years ended december  and  respectively 
the decrease in was due primarily to decreasing average investment balances 
other gains and losses 
we had other gains of  for the year ended december  and other losses of  for the year ended december  the gains during relate to proceeds from a sale of securities in connection with an earlier license agreement signed in with imagyn medical technologies  inc formerly urohealth systems  inc  while the losses during relate to recognition of a permanent reduction in value of those securities 
liquidity and capital resources net cash used in operating activities was approximately   and  in  and  respectively 
the decrease in net cash used in operating activities during compared to was primarily attributable to decreasing net losses and lower inventory purchases offset by lower non cash expenses for depreciation and amortization 
the decrease in net cash used in operating activities during compared to was primarily attributable to decreasing net losses and lower inventory purchases offset by lower non cash expenses for depreciation and amortization and no customer advance payments in compared to net cash used in investing activities was approximately  in and net cash provided by investing activities was approximately  and  in and  respectively 
the decrease in net cash provided by investing activities in compared to was primarily attributable to declining balances of short term investments reaching maturity partially offset by decreasing purchases of property and equipment 
the decrease in net cash provided by investing activities in compared to was also primarily attributable to declining balances of short term investments reaching maturity partially offset by decreasing purchases of property and equipment 
cash flows from financing activities were   and  in  and  respectively 
the cash flows from financing activities during the period were primarily attributable to the sale of stock to three of our stockholders with net proceeds of approximately  along with an increase in purchases of stock by employees through our employee stock purchase plan  partially offset by a lower level of stock option exercises 
the cash flows from financing activities in and were primarily attributable to proceeds from the purchase of stock by employees through our employee stock purchase plan and the exercise of stock options 
we recently announced that we are working on a strategic initiative to extend our business to become more involved in the medical treatment of severe obesity 
if we decide to pursue this initiative  we will be required to raise additional funds to support our operations 
in addition  if we are unable to sustain our cash flow under our current business plan  we will be required to raise additional funds 
if we are unable to raise sufficient funds from an offering of securities or otherwise  we may be unable to continue operations at their current level and may be unable to pursue this new objective 
even if we are successful in raising additional funds  circumstances  including slow rate of market acceptance of our products or our inability to scale up manufacturing  would accelerate our use of proceeds from any offering we might do and require us to seek additional funds to support our operating requirements 
item a 
quantitative and qualitative disclosures about market risk at december   our investment portfolio included fixed income securities of million 
these securities are subject to interest rate risk and will decline in value if interest rates increase 
due to the short term nature of our investment portfolio  an immediate percent increase in interest rates would have no material impact on our financial condition or results of operations 
we generally conduct business  including sales to foreign customers  in us dollars and as a result have limited foreign currency exchange rate risk 
the effect of an immediate percent change in foreign exchange rates would not have a material impact on our financial condition or results of operations 

